-
1.发明申请公开(公告)号：US20200332011A1
公开(公告)日：2020-10-22
申请号：US16852508
申请日：2020-04-19
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
IPC: C07K16/28
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
2.发明授权公开(公告)号：US09314483B2
公开(公告)日：2016-04-19
申请号：US14303212
申请日：2014-06-12
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventor： Michal Eisenbach-Schwartz , Ester Yoles , Ravid Shechter , Omer Miller
IPC: C12N5/0786 , A61K35/15 , A61K35/14 , A61K35/12
CPC classification number: A61K35/15 , A61K35/14 , A61K2035/124 , C12N5/0645
Abstract: A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3+ cells, CD19+ cells, CD56+ cells and optionally of CD16+ cells, for use in treatment of CNS injury is provided.
Abstract translation: 提供了用于治疗CNS损伤的基本上不含CD3 +细胞，CD19 +细胞，CD56 +细胞和任选的CD16 +细胞的外周血单核细胞（PBMC）的亚群。
-
公开(公告)号：US10188679B2
公开(公告)日：2019-01-29
申请号：US14898732
申请日：2014-05-22
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Ester Yoles , Inbal Benhar Bar-On
Abstract: A monocyte subpopulation having a low relative amount, or substantially devoid, of CD3+ cells, CD19+ cells, CD56+ cells and optionally CD16+ cells is provided, wherein the monocyte subpopulation is for use in inhibition of neuronal degeneration, protection of neurons from glutamate toxicity or promotion of nerve regeneration in the retina or optic nerve, wherein the retina or optic nerve is damaged by a disease, disorder or condition of the eye, or for treatment of an inflammatory disease, disorder or condition of the eye.
-
4.发明申请HUMAN MONOCYTE SUB-POPULATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM INJURY 有权用于治疗中枢神经系统损伤的人类单克隆人群公开(公告)号：US20140363411A1
公开(公告)日：2014-12-11
申请号：US14303212
申请日：2014-06-12
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventor： Michal Eisenbach-Schwartz , Ester Yoles , Ravid Schechter , Omer Miller
IPC: A61K35/14
CPC classification number: A61K35/15 , A61K35/14 , A61K2035/124 , C12N5/0645
Abstract: A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3+ cells, CD19+ cells, CD56+ cells and optionally of CD16+ cells, for use in treatment of CNS injury is provided.
Abstract translation: 提供了用于治疗CNS损伤的基本上没有CD3 +细胞，CD19 +细胞，CD56 +细胞和任选的CD16 +细胞的外周血单核细胞（PBMC）的亚群。
-
5.发明授权公开(公告)号：US11732046B2
公开(公告)日：2023-08-22
申请号：US17222370
申请日：2021-04-05
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
CPC classification number: C07K16/2827 , A61K2039/505 , C07K2317/515 , C07K2317/56
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US10995141B2
公开(公告)日：2021-05-04
申请号：US16852508
申请日：2020-04-19
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
7.发明公开公开(公告)号：US20240052038A1
公开(公告)日：2024-02-15
申请号：US18360222
申请日：2023-07-27
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
IPC: C07K16/28
CPC classification number: C07K16/2827 , A61K2039/505
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
8.发明申请公开(公告)号：US20210221893A1
公开(公告)日：2021-07-22
申请号：US17222370
申请日：2021-04-05
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
IPC: C07K16/28
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
公开(公告)号：US09517256B2
公开(公告)日：2016-12-13
申请号：US14162482
申请日：2014-01-23
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Michal Eisenbach-Schwartz , Ester Yoles , Oleg Butovsky , Jonathan Kipnis
IPC: A61K39/00
CPC classification number: A61K39/0007 , A61K39/00 , A61K39/0008 , A61K2039/5158
Abstract: Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).
Abstract translation: 提供方法和组合物用于治疗除了朊病毒疾病之外存在错误折叠和/或聚集蛋白质积累的神经变性疾病。 特别地，本发明涉及治疗神经退行性疾病亨廷顿病（HD），阿尔茨海默病（AD）或帕金森病（PD）），通过施用选自（i）共聚物1，（ii） 共聚物1相关肽，（iii）共聚物1相关多肽，和（iv）用（i），（ii）或（iii）活化的T细胞。
-
10.发明申请CELLULAR MARKERS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE AND FOR ALZHEIMER'S DISEASE PROGRESSION 审中-公开用于诊断阿尔茨海默病和阿尔茨海默氏病进展的细胞标志物公开(公告)号：US20150057176A1
公开(公告)日：2015-02-26
申请号：US14388369
申请日：2013-03-21
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD. , NEUROQUEST LTD.
Inventor： Michal Eisenbach-Schwartz , Ester Yoles
IPC: G01N33/569 , G01N33/50
CPC classification number: G01N33/56972 , G01N33/5047 , G01N33/505 , G01N2800/2821 , G01N2800/50 , G01N2800/52
Abstract: The present invention provides methods for early diagnosis of Alzheimer's disease and for determining the efficacy of a treatment for Alzheimer's disease in an Alzheimer's patient, i.e., monitoring Alzheimer's disease progression, utilizing cellular blood markers; as well as kits for carrying out these methods.
Abstract translation: 本发明提供早期诊断阿尔茨海默氏病和确定阿尔茨海默病患者阿尔茨海默病治疗功效的方法，即利用细胞血标记物监测阿尔茨海默病进展; 以及执行这些方法的工具包。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.021 seconds)
